Guardant Health, Inc. (GH)
NASDAQ: GH · Real-Time Price · USD
102.02
-6.50 (-5.99%)
At close: Dec 5, 2025, 4:00 PM EST
101.99
-0.03 (-0.03%)
After-hours: Dec 5, 2025, 7:55 PM EST
Guardant Health Stock Forecast
Stock Price Forecast
The 21 analysts that cover Guardant Health stock have a consensus rating of "Strong Buy" and an average price target of $79.19, which forecasts a -22.38% decrease in the stock price over the next year. The lowest target is $55 and the highest is $130.
Price Target: $79.19 (-22.38%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Guardant Health stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 8 | 8 | 8 |
| Buy | 10 | 10 | 14 | 15 | 15 | 13 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 21 | 23 | 23 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Maintains $105 → $130 | Buy | Maintains | $105 → $130 | +27.43% | Dec 2, 2025 |
| UBS | UBS | Strong Buy Maintains $80 → $110 | Strong Buy | Maintains | $80 → $110 | +7.82% | Oct 30, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $65 → $100 | Strong Buy | Maintains | $65 → $100 | -1.98% | Oct 30, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $68 → $90 | Buy | Maintains | $68 → $90 | -11.78% | Oct 30, 2025 |
| Barclays | Barclays | Buy Maintains $70 → $85 | Buy | Maintains | $70 → $85 | -16.68% | Oct 30, 2025 |
Financial Forecast
Revenue This Year
995.57M
from 739.02M
Increased by 34.72%
Revenue Next Year
1.26B
from 995.57M
Increased by 26.46%
EPS This Year
-2.02
from -3.56
EPS Next Year
-2.21
from -2.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 1.0B | 1.4B | ||||
| Avg | 995.6M | 1.3B | ||||
| Low | 903.7M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 37.9% | 39.7% | ||||
| Avg | 34.7% | 26.5% | ||||
| Low | 22.3% | 12.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.79 | -0.93 | ||||
| Avg | -2.02 | -2.21 | ||||
| Low | -3.04 | -3.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.